(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the first quadrivalent influenza vaccine, an inhaled live attenuated influenza vaccine developed by MedImmune and modeled after its FluMist product.
The vaccine includes a second influenza B strain, which is designed to broaden protection against circulating strains. MedImmune plans to have the quadrivalent vaccine ready for the 2013-14 flu season.
(CIDRAP News) – Novartis's new cell-culture based influenza vaccine factory in North Carolina has begun making a prepandemic H5N1 flu vaccine and is ready to start producing vaccines for a real pandemic when needed, the company and federal health officials announced yesterday.
The facility in Holly Springs, N.C., billed as the first of its kind in the United States, was dedicated yesterday after a long testing process.
(CIDRAP News) A new report says that a cell culture derived influenza vaccine and a conventional egg-based vaccine both proved effective in a large international clinical trial, offering support for those who contend that cell-based vaccines should become an important part of flu vaccine supplies in coming years.
(CIDRAP News) Large trials in three countriesthe United States, Hungary, and Chinarecently confirmed the safety and efficacy of H1N1 vaccines, yielding new insights on how to best use vaccines in a pandemic setting.
(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.